Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

Systematic review and meta-analysis of randomized controlled trials

“We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of cagrilintide-based therapies in adults with overweight or obesity.”

Adults with overweight or obesity

“Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.”

5,023 participants from four trials

“Four trials including 5,023 participants were pooled.”

Cagrilintide and CagriSema significantly reduced percent body weight compared to placebo

“Cagrilintide significantly reduced percent body weight versus placebo (mean difference − 6.08%, 95% CI − 8.02 to − 4.14), as did CagriSema (− 5.98%, 95% CI − 10.64 to − 1.32).”

CagriSema reduced waist circumference and HbA1c, while cagrilintide alone showed modest blood pressure improvements

“CagriSema produced a significant reduction in waist circumference and HbA1c, whereas cagrilintide alone showed modest blood pressure improvements without significant glycemic effects.”

Overall adverse events were more frequent with active treatment, but discontinuation rates were comparable to placebo

“Overall adverse events were more frequent with active treatment, but discontinuation rates were comparable to placebo.”